ArticleNeuro-oncology2024

Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma.

Sara Hiller-Vallina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.